Suggestions
Bernard Fox
Internationally recognized leader in immuno-oncology
Bernard A. Fox, PhD, is an internationally recognized leader in immuno-oncology and the Co-Founder, President, and CEO of UbiVac, a clinical stage immuno-oncology company.1 He has held this position at UbiVac since 2005, focusing on the research, development, and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases.1
Professional Background
Dr. Fox has an extensive background in cancer research and immunotherapy:
Academic Positions::
- Harder Family Endowed Chair for Cancer Research at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center (1994-present)1
- Guest Professor at Xian Jiaotung University, China (1999-2008)1
- Guest Professor at Ludwig-Maximilians-University, Department of Surgery (2001-2002)1
Research Experience::
- Senior Staff Fellow and Staff Fellow at the National Cancer Institute (1985-1990)1
- Surgical Oncology at the University of Michigan Medical School (1990-1994)1
Leadership Roles
Dr. Fox has held several leadership positions in professional organizations:
- Chair of the World Immunotherapy Council (2012-present)1
- Ambassador for the Society for Immunotherapy of Cancer (SITC) (2012-present)1
- Vice President of the International Society for Biological Therapy of Cancer (iSBTc, now SITC) (2006-2008)1
Education
- PhD in Regulatory Cell Biology and Biophysics from Wayne State University (1979-1985)1
- MS in Immunology from the University of Detroit Mercy (1975-1978)1
- Staff Fellow in Cancer Immunotherapy at the National Cancer Institute, NIH (1985-1990)1
Recent Achievements
In 2024, Dr. Fox was honored with a Society for Immunotherapy of Cancer Lifetime Achievement Award, recognizing his significant contributions to the field of cancer immunotherapy.3
Bernard A. Fox continues to be actively involved in cancer research and immunotherapy development, regularly participating in international conferences and discussions on breakthroughs in cancer immunotherapy.2
Highlights
Thank you Helen Raptis & KATU for chance to talk a bit about the potential of #Cancer #immunotherapy to CURE patients with cancer. Honor to mention Linda Taylor who was the first patient cured of #melanoma with #IL2 and was treated by Dr. Steven A Rosenberg @ Surgery Branch, National Cancer Institute (NCI)
https://lnkd.in/gdB3FGn8
Also mentioned combining cancer #vaccines + #PD1 has increased response rates in #pancreatic cancer, melanoma, & #headandneck cancer. More on cancer’s #DarkMatter at VAX ON Oct 1, 2024 in Milan
https://lnkd.in/gv76WhSY
and at #SITC2024 Society for Immunotherapy of Cancer (SITC) Moderna BioNTech SE UbiVac Incyte Merck Genentech
https://lnkd.in/gNRpefBy
Paolo A. Ascierto Ryan Sullivan Bhardwaj Nina jonathan yewdell Kees Melief Rom Leidner William Freed-Pastor Inge Marie Svane Pablo Guasp, PhD Pierre Thibault Drs Leo Zhang & Erwei Song
Thanks OncoDaily. To be clear, In my opinion, to get to 100 new I-O drugs in 10yrs we will need #vaccines. #Cancervaccines are back and at least 3 companies (Moderna BioNTech SE and UbiVac ) have recent strong clinical data because they immunize to important targets on cancer and they are combined with checkpoint blockade. One of these 3 vaccines is from UbiVac , It is not personalized, is off-the-shelf, contains the newly discovered cancer’s “Dark Matter”, and has doubled to more than tripled response rates in patients with #headandneck #cancer. This vaccine was designed not just for head and neck cancer, but to treat the majority of solid cancers, including #lungcancer , #breastcancer and #prostatecancer. UbiVac’s current clinical trial is supported by Incyte and UbiVac is excited to start the next phase of the vaccine’s clinical development at multiple centers. UbiVac is currently looking for #investors to expand vaccine manufacturing. Interested parties can find information at www.ubiVac.com. https://lnkd.in/gxU-Xcq4.
